“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps This study aimed to evaluate the feasibility of extending dupilumab dosing intervals in T2-CRSwNP by assessing how many patients maintain disease control with once-every-12-weeks (Q12W) dosing and co....

A new study finds that some patients on #dupilumab for chronic rhinosinusitis with nasal polyps are "super-responders", successfully maintaining disease control with a single dose 💊 just once every 12 weeks.

#CRSwNP #biologics #type2disease #Immunology

🔗 ino.to/WtzjQlV